Scandinavian Business Awards 2026 Patient-Centric Clinical Research Champions of the Year 2026 – Denmark This year's Scandinavian Business Awards are, once again, home to accolade-worthy enterprises positively impacting not only this respective region but also the rest of the world. With a strong Scandinavian presence and a global network of qualitative researchers, CLINIGMA® is an international clinical research organization which serves pharmaceutical companies across Europe, North America, Asia, and beyond. We learn more from Founder and CEO Jens Harald Kongsø as this outstanding CRO is awarded in our Scandinavian Business Awards 2026. On a mission to bring clarity and value to pharmaceutical companies by being their trial patients' structured voice, CLINIGMA® is a proud partner of several of the world's largest pharmaceutical companies for whom it conducts “in-trial patient interviews at any stage of drug development, capturing the patient voice to support regulatory submissions, labelling claims, and commercial decision-making.” Founder and CEO, Jens Harald Kongsø, continued: “We also work with companies in rare disease, where hearing directly from patients is a critical part of building a strong regulatory case.” Serving pharmaceutical companies across Europe, North America, Asia, and beyond, CLINIGMA® continues to elevate the pharmaceutical industry from within. Jens told us: “At the heart of what we do is capturing patients' experiences in their own words during clinical trials, through our secure CLINIGMA® Portal, the first system purpose-built for this work. Recognised as a best-in-class solution, our Portal ensures full ICH-GCP compliance, translating authentic patient experiences into regulatory-grade evidence.” “We believe that patient-centricity should be an important part of the scientific work when developing new drugs.” By being a pharmaceutical company's trusted interview partner, CLINIGMA® exercises its combination of “clinical expertise, methodological discipline, and genuine empathy for what trial participants are going through.” That combination is what allows the organization to deliver rigorous, regulatory-grade evidence while keeping the patient experience at the centre of every study. Jens said: “What sets us apart is what we bring to every project while complying fully with ICH-GCP. Our scientific team has extensive experience in conducting qualitative research in relation to clinical trials, helping inform drug development and support commercial decision-making. Behind every study is a global network of 300+ Master's and PhD-level researchers, each trained in ICH-GCP and project-specific requirements to ensure patient safety, ethics, and high-quality data collection.” “The CLINIGMA® Portal makes every aspect of the interview process easy, secure, and ICH-GCP compliant, optimising data collection, patient privacy, and safety. And our project management team handles every step of the process, so clients don't have to. From study design to delivery, we take the complexity off their plate and deliver timely patient insights.” The team at CLINIGMA® ensures that the organization is always in alignment with both global and local regulatory frameworks, so that every pharmaceutical company knows they are in entirely safe hands. Jens shared: “We ensure data integrity, patient safety, and transparency at every stage. Clients don't just get a service provider. They get a trusted partner that is genuinely passionate about advancing healthcare and improving patient outcomes.” 2026 is set to be another highly significant year for CLINIGMA® as it recently launched the CLINIGMA® Explorer, a new solution that gives pharmaceutical teams direct access to interview transcripts, rather than just receiving a final report. Jens told us: “With Explorer, clients can filter by patient characteristics, emerging themes, symptoms, and even integrate with COA data, as well as compare sections from multiple transcripts side by side. As the future beckons, CLINIGMA® is also growing its educational presence. Jens enthused: “We have a webinar series launching on Xtalks later this year, which will be focused on the regulatory and practical foundations of in-trial patient interviews. And as patientfocused drug development guidance continues to mature in both the US and EU, we're positioning to help clients get ahead of those requirements rather than react to them.” We look forward to seeing what comes next for CLINIGMA® and we're proud to award the organization with its title of Patient-Centric Clinical Research Champions of the Year 2026 – Denmark. Contact: Jens Harald Kongsø Company: CLINIGMA® Website: https://www.clinigma.com/
RkJQdWJsaXNoZXIy MTUyMDQwMA==